Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06728007

Nephrological Outcome and Associated Congenital Anomalies in Pediatric Patients with Horseshoe Kidney

A retrospective, observational multicentre trial on the nephrological outcome and associated congenital anomalies in children with Horseshoe Kidney.

Recruiting

Interested in participating?

Request Info

Key information

Age range

Up to 18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, 40138, Italy

Location status: Recruiting

Location contact

Claudio La Scola

CONTACT

Claudio La Scola, MD, PhD

CONTACT

[email protected]

00390512144650

About this study

Congenital abnormalities of the kidney and urinary tract (CAKUT) represent the main cause of CKD in children. Among them, the horseshoe kidney (HSK) represents one of the most frequent and is characterised by the presence of two distinct, functioning kidneys positioned on each side of the spine, fused together at one of the poles. The incidence of this condition is approximately 1 case every 400-600 new births with a prevalence in the male sex with a ratio of 2:1. Even though these children aregenerally asymptomatic and the diagnosis is often incidental , some may develop symptoms due to complications, such as infections, nephrolithiasis and urinary tract obstruction. More rarely risks of neoplastic degeneration and renal damage are described following trauma to the abdomen and lumbosacral spine. This condition is also associated in up to a third of cases with other abnormalities: the most frequent affect the urinary tract and genitals; however, abnormalities affecting other organs or systems as well as well-defined syndromic pictures. Due to its frequent asymptomatic nature, horseshoe kidney is historically considered a condition with a good prognosis and rarely as a risk factor capable of reducing survival or predisposing the kidney to long-term damage.

The primary objective of the study is:

To assess the 'nephrological outcome' understood as 'prevalence of patients who developed' and 'survival time free from": chronic renal failure, proteinuria, hypertension nephrolithiasis, UTI, renal neoplasms and renal trauma.

The secondary objectives of the study are:

  • Prevalence of congenital and associated genito-urinary and systemic abnormalities;
  • Description of renal anatomical features;
  • Assessment of the usefulness of second level radiological investigations (VCUG, static renal scintigraphy, ddynamic renal scintigraphy).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with confirmed ultrasound and/or scintigraphic diagnosis of horseshoe kidney;
  • Patients with an age at first assessment of between 0 and 18 years;
  • Obtaining written Informed consent.

Exclusion criteria

  • Patients with a definitive diagnosis of another form of CAKUT during the diagnostic pathway.

Treatment and study plan

Primary outcomes

  1. Chronic kidney disease

    Time frame: at baseline

    Defined as a reduction in eGFR <90ml/min/1.73m2, calculated using the Schwartz formula(18) corrected for age:

    • δ= 0.45 for children <1 yr
    • δ= 0.55 for children of both sexes from 2 to 12 yrs and for female children aged 13 to 18 yrs
    • δ= 0.70 for children aged 13 to 18 yrs

    The different stages of chronic kidney have been further defined according to eGFR:

    • Stage I: >90ml/min/1.73m2
    • Stage II: between 89 and 60ml/min/1.73m2
    • Stage III: between 59 and 30ml/min/1.73m2
    • Stage IV: between 30 and 15ml/min/1.73m2
    • Stadio V: lower than15ml/min/1.73m2 or patient in dialysis
  2. Proteinuria

    Time frame: at baseline

    Defined as the urinary protein:creatinine ratio (mg/mg) >0.5 in chilrden up to 2 yrs of age and >0.2 in chilrden older than 2 yrs

  3. Hypertension

    Time frame: at baseline

    Arterial blood pressure ≥95th percentile for sex, age and height, on at least three different readings

Secondary outcomes

  1. Urinary tract infections

    Time frame: at baseline

    Confirmed by urine analysis and urine culture in a compatible clinical picture

  2. Nephrolithiasis

    Time frame: at baseline

    Documented finding by imaging techniques (ultrasound and/or CT) of formations compatible with lithiasis formation

  3. Renal neoplasms

    Time frame: at baseline

    Diagnosis confirmed by imaging and histology of the neoplasm of renal origin (especially Wilms' tumour)

  4. Renal anatomical features

    Time frame: at baseline

    Renal length measured as bipolar diameter with renal hypoplasia defined as the presence of kidneys with DBP <5° centile reference for age and height

  5. Renal anatomical features

    Time frame: at baseline

    Ultrasound description of abnormalities of the renal parenchyma with renal dysplasia defined by the presence of alterations such as: hyperechogenicity, reduced cortico-middular differentiation, reduced cortical thickness due to age, presence of multiple cystic formations

  6. Renal trauma

    Time frame: at baseline

    Presence of instrumentally documented renal lesions (ultrasound and/or CT scan) following a traumatic episode

Study contacts

Contact information is provided by the study sponsor or research team.

Claudio La Scola, MD, PhD

CONTACT

[email protected]

00390512144650

Sponsors and collaborators

Lead sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 11, 2024
Registry last updated
Dec 11, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.